XML 9 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 10,362 $ 11,055
Available-for-sale investments 65,987 61,070
Other receivables 988 1,736
Prepaid expenses 5,934 8,093
Total current assets 83,271 81,954
Restricted cash 2,432 2,951
Property and equipment, net 4,683 4,850
Operating lease, right-of-use assets 5,750 5,817
Financing lease, right-of-use assets 1,043 1,192
Other assets 66 66
Total assets 97,245 96,830
Current liabilities:    
Accounts payable 1,531 4,323
Accrued expenses 7,862 9,392
Current portion of operating lease liability 740 711
Current portion of financing lease liability 550 541
Total current liabilities 10,683 14,967
Long-term operating lease liability, net of current portion 10,953 11,144
Long-term financing lease liability, net of current portion 747 887
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of March 31, 2025 (unaudited) and December 31, 2024, no shares issued or outstanding as of March 31, 2025 (unaudited) and December 31, 2024
Common stock, $0.001 par value per share; 170,000,000 authorized shares as of March 31, 2025 (unaudited) and December 31, 2024, issued and outstanding shares - 89,002,825 as of March 31, 2025 (unaudited) and 84,038,922 as of December 31, 2024 89 84
Additional paid-in capital 621,953 602,021
Accumulated other comprehensive loss (66) (40)
Accumulated deficit (546,926) (532,046)
Total aTyr Pharma stockholders’ equity 75,050 70,019
Noncontrolling interest in Pangu BioPharma Limited (188) (187)
Total stockholders' equity 74,862 69,832
Total liabilities and stockholders’ equity $ 97,245 $ 96,830